Harvard Bioscience, Inc.
HBIO
$0.762
-$0.0119-1.54%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -13.15% | -11.36% | -6.76% | -0.96% | -4.61% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -13.15% | -11.36% | -6.76% | -0.96% | -4.61% |
| Cost of Revenue | -11.31% | -13.51% | -9.85% | -7.81% | -12.75% |
| Gross Profit | -14.39% | -9.78% | -4.47% | 4.40% | 1.83% |
| SG&A Expenses | -4.19% | -2.10% | -3.29% | -3.77% | -7.10% |
| Depreciation & Amortization | -6.64% | -9.48% | -9.50% | -9.75% | -2.96% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -6.31% | -6.49% | -5.44% | -5.89% | -9.40% |
| Operating Income | -252.25% | -341.67% | -6,868.18% | 175.79% | 212.31% |
| Income Before Tax | -469.64% | -45.67% | -764.47% | 72.15% | 67.23% |
| Income Tax Expenses | -3.81% | 219.64% | -54.34% | 154.90% | 443.82% |
| Earnings from Continuing Operations | -336.44% | -96.68% | -333.52% | 64.11% | 52.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -336.44% | -96.68% | -333.52% | 64.11% | 52.63% |
| EBIT | -252.25% | -341.67% | -6,868.18% | 175.79% | 212.31% |
| EBITDA | -76.63% | -65.14% | -25.60% | 121.64% | 117.07% |
| EPS Basic | -326.79% | -90.52% | -326.26% | 65.15% | 53.73% |
| Normalized Basic EPS | -3,340.82% | -146.25% | -176.46% | 64.00% | 94.09% |
| EPS Diluted | -302.30% | -87.81% | -292.56% | 63.12% | 52.55% |
| Normalized Diluted EPS | -3,205.88% | -145.20% | -180.16% | 63.41% | 93.87% |
| Average Basic Shares Outstanding | 2.33% | 2.42% | 2.39% | 2.17% | 2.58% |
| Average Diluted Shares Outstanding | 1.93% | 2.02% | 1.23% | 1.80% | 0.67% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
